Background Schizophrenia is a common, severe, and usually chronic disorder. Maintenance
treatment with antipsychotic drugs can prevent relapse but also causes side-effects. We …

Originally published in February 2004. This guideline is more than 5 years old and has not
yet been updated to ensure that it reflects current knowledge and practice. In accordance …

Among individuals diagnosed, hospitalized, and treated for schizophrenia, up to 40% of
those discharged may relapse within 1 year even with appropriate treatment. Passively …

Importance Long-acting injectable antipsychotics (LAIs) can potentially reduce
hospitalization risk by enhancing medication adherence but are rarely considered for early …

Although non‐adherence is common across all branches of medicine, psychotic disorders
pose additional challenges that increase its risk. Despite the importance of non‐adherence …

According to current evidence and guidelines, continued antipsychotic treatment is key for
preventing relapse in people with schizophrenia‐spectrum disorders, but evidence‐based …

Background The relative effectiveness of second-generation (atypical) antipsychotic drugs
as compared with that of older agents has been incompletely addressed, though newer …

These updated guidelines are based on a first edition of the World Federation of Societies of
Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia …

In light of the large number of studies published since the 2004 update of Schizophrenia
Patient Outcomes Research Team psychopharmacological treatment recommendations, we …

In this issue of Structure, Holmes et al.(2005) describe elements of an innate defense
mechanism that provides mammals a means to restrict bacterial growth. The host protein …